[Clinical evaluation of fluconazole in patients with mycotic infection].
Fluconazole, a triazole antifungal agent newly developed by Pfizer Inc.. was given orally to 4 patients with deep mycosis. Fluconazole was markedly effective against septicemia due to Candida and oral candidiasis accompanied with lingual ulcer in spite of seriousness of these underlying disease. In 2 patients with aspergilloma, eradication or contraction of fungus ball was observed and the drug was judged to be effective. In vitro MICs of fluconazole against clinically isolated Aspergillus spp. were much higher than its serum levels leaving a large discrepancy between in vitro activity and clinical efficacy. Although the dosage was 100-300 mg daily for 8 days to 6 months, neither adverse reactions nor laboratory parameter abnormalities were observed. The above results suggest that fluconazole is a useful agent in the treatment of fungal infections.
Matsushima
T
T
2nd Department of Internal Medicine, Kawasaki Medical School, Kawasaki Hospital, Okayama.
Ikeda
H
H
Tomizawa
S
S
Nakamura
J
J
Adachi
M
M
Kawanishi
M
M
Tanabe
J
J
Tano
Y
Y
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy / Q000382:microbiology; D001230:Aspergillus / Q000187:drug effects; D002177:Candidiasis / Q000188:drug therapy; D002180:Candidiasis, Oral / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D015725:Fluconazole; D006801:Humans; D008168:Lung / Q000378:metabolism; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000382:microbiology; D008297:Male; D008826:Microbial Sensitivity Tests; D009181:Mycoses / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D018805:Sepsis / Q000188:drug therapy; D014018:Tissue Distribution; D014230:Triazoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
D000935:Antifungal Agents; D014230:Triazoles; D015725:Fluconazole